Your browser doesn't support javascript.
loading
Peer support impact on therapeutic adherence in patients with multiple sclerosis: a mixed-methods pilot trial protocol.
Guilmault, Léonor; Wiertlewski, Sandrine; Malloggi, Lucie; Rousseau, Cécilia; Jacq-Foucher, Marylène; Leclere, Brice; Moret, Leila.
Afiliación
  • Guilmault L; Service de santé publique, Nantes University Hospital, Nantes, France.
  • Wiertlewski S; Service de neurologie, Nantes University Hospital, Nantes, France.
  • Malloggi L; Service de santé publique, Nantes University Hospital, Nantes, France.
  • Rousseau C; Service de santé publique, Nantes University Hospital, Nantes, France.
  • Jacq-Foucher M; Service de neurologie, Nantes University Hospital, Nantes, France.
  • Leclere B; Service de santé publique, Nantes University Hospital, Nantes, France.
  • Moret L; Service de santé publique, Nantes University Hospital, Nantes, France leila.moret@chu-nantes.fr.
BMJ Open ; 13(12): e071336, 2023 12 30.
Article en En | MEDLINE | ID: mdl-38159942
ABSTRACT

INTRODUCTION:

Patient partnership is a key component of patient-centred care. One form of partnership is individual peer support, which can improve patients' quality of life and adherence to treatment. Patient with multiple sclerosis could benefit from this type of support, but such an intervention has not been explored in the literature.We propose in this article a pilot study protocol to assess the feasibility and acceptability of healthcare-integrated individual peer support, and the feasibility of a large-scale efficacy trial. METHODS AND

ANALYSIS:

The PAIR-SEP study is a mixed-methods pilot clinical trial combining quantitative and qualitative approaches. Sixty patients with relapsing-remitting multiple sclerosis undergoing drug therapy from the Neurology centre of Nantes University Hospital (France) will be randomised on a 11 ratio to receive either usual care only or usual care combined with peer support (three individual sessions at 1, 3 and 5 months with a peer helper).We will evaluate clinical outcomes in preparation of the large-scale trial therapeutic adherence 6 months after baseline, therapeutic compliance, quality of life, anxiety and depression, social support. All dimensions will be assessed using validated health questionnaires at baseline and at 6 months.Intervention's acceptability and feasibility will be evaluated using qualitative

methods:

undirected interviews with patients from the intervention group and separate focus-groups with the peer helpers the healthcare team. ETHICS AND DISSEMINATION Ethical approval was obtained from the local ethics committee on 1 October 2022. This study was designed in collaboration with multiple sclerosis peer helpers.The trial findings will be published in peer-reviewed journals. TRIAL REGISTRATION NUMBER NCT05519553.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Límite: Humans Idioma: En Revista: BMJ Open Año: 2023 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Límite: Humans Idioma: En Revista: BMJ Open Año: 2023 Tipo del documento: Article País de afiliación: Francia
...